遺伝子治療によりマウスの脳腫瘍を安全に除去(Gene therapy safely eradicates brain tumours in mice)

ad

2026-04-08 エディンバラ大学

エディンバラ大学の研究チームは、マウスにおいて脳腫瘍を安全に除去できる遺伝子治療法を開発した。腫瘍細胞に選択的に作用する遺伝子を導入し、がん細胞のみを標的として破壊することで、正常な脳組織への影響を最小限に抑えた点が特徴である。この治療は免疫応答も活性化し、腫瘍の再発抑制にも寄与する可能性が示された。従来の外科手術や放射線治療と比べて低侵襲で安全性が高く、前臨床段階ながら有望な結果が得られている。今後はヒトへの応用に向けた検証が必要だが、難治性脳腫瘍に対する新たな治療戦略として期待される。

<関連情報>

合成スーパーエンハンサーにより精密なウイルス免疫療法が可能になる Synthetic super-enhancers enable precision viral immunotherapy

Ute Koeber,Mantas Matjusaitis,Neza Alfazema,Katharine Furlong,Zeyu Wang,Rachel White,Alhafidz Hamdan,Pooran Dewari,Gregoire Morisse,Mariela Navarette,Rosie Willis,Jin Wang,Michelle P. Clark,Carla Jacinto de Sousa,Hei Ip Hong,Shahida Sheraz,Ben Southgate,Justyna Cholewa-Waclaw,Sabine Gogolok,Gillian M. Morrison,Felipe Galvez Cancino,Faye Robertson,Anna Williams,Susan J. Rosser,… Steven M. Pollard
Nature  Published:08 April 2026
DOI:https://doi.org/10.1038/s41586-026-10329-6

遺伝子治療によりマウスの脳腫瘍を安全に除去(Gene therapy safely eradicates brain tumours in mice)

Abstract

Cell-type-specific promoters are used in gene therapy to restrict expression of the therapeutic payload. However, these promoters often have suboptimal strength, selectivity and size. Here, leveraging recent insights into the function of enhancers, we developed synthetic super-enhancers (SSEs) by assembling functionally validated enhancer fragments into multipart arrays. Focusing on the core SOX2-driven and SOX9-driven transcriptional regulatory network in glioblastoma stem cells (GSCs)1, we engineered SSEs with robust activity and high selectivity. Single-cell profiling, biochemical analyses and genome-binding data indicated that SSEs integrate neurodevelopmental and signalling-state transcription factors to trigger the formation of large multimeric complexes of transcription factors. Moreover, GSC-selective expression of a combination of cytotoxic (HSV-TK and ganciclovir) and immunomodulatory (IL-12) payloads, delivered using adeno-associated virus vectors, as a single treatment led to curative outcomes in a mouse model of aggressive glioblastoma. Notably, IL-12 induced an immunological memory that prevented tumour recurrence. The activity and selectivity of the adeno-associated virus and SSE were validated using primary human glioblastoma tissue and normal cortex samples. In summary, SSEs harness the unique core transcriptional programs that define the GSC phenotype and enable precision immune activation. This approach may have broader applications in other contexts when precise control of transgene expression in specific cell states is necessary.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました